DarshanTalks Podcast – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

DarshanTalks Podcast

Darshan Kulkarni

Sciences

Éducation

Société & Culture

Fréquence : 1 épisode/3j. Total Éps: 350

Welcome to DarshanTalks!

We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!

Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.

We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career.

Lire plusRéduire

Site

RSS

Apple

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇨🇦 Canada - lifeSciences
12/08/2026
#92
🇨🇦 Canada - lifeSciences
11/08/2026
#82
🇨🇦 Canada - lifeSciences
10/08/2026
#75
🇨🇦 Canada - lifeSciences
09/08/2026
#62
🇨🇦 Canada - lifeSciences
08/08/2026
#51
🇨🇦 Canada - lifeSciences
07/08/2026
#45
🇨🇦 Canada - lifeSciences
06/08/2026
#29
🇨🇦 Canada - lifeSciences
31/07/2025
#91
🇨🇦 Canada - lifeSciences
30/07/2025
#75
🇨🇦 Canada - lifeSciences
29/07/2025
#65

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://www.buzzsprout.com/2239432/support
347 partages
https://www.buzzsprout.com/2239432/fan_mail/new
347 partages

https://www.youtube.com/watch?v=I53cxReeAQM&amp
20 partages
https://www.youtube.com/watch?v=uUKhGF_0-Hs&amp
14 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 48%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Your Mood, Energy, and Sleep Claims Might Be Regulated

jeudi 11 décembre 2025 • Durée 01:04

Send us Fan Mail

A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing often becomes bolder, and that’s where risk creeps in. The FDA steps in when your claims imply treating or preventing a disease, which can flip your product into drug or device territory. The FTC expects every wellness claim to be truthful and supported by real evidence. In this episode, I explain how I review labels, websites, and social content, map each claim to the right regulatory bucket, and draft compliant alternatives that keep your marketing appealing without triggering expensive oversight. I also build claim checklists to help teams avoid drift in the future. Call, click, or email if you need support.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Device Fail: The Legal Anatomy of a Faulty Implant Scandal

mercredi 10 décembre 2025 • Durée 04:58

Send us Fan Mail

A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selling a product they allegedly knew would fail. This episode breaks down the Aesculap case, the $38.5M settlement, and what it teaches us about kickbacks, forged FDA documents, and the catastrophic cost of weak compliance controls. If your team works in pharma, med-tech, or clinical research, you don’t want to miss this one.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Compliance guru talks practical Insights on Speaker Programs

vendredi 7 novembre 2025 • Durée 13:11

Send us Fan Mail

In this episode, host Darshan Kulkarni speaks with Joseph Keeney about speaker programs in the life sciences industry, exploring practical differences between small and large companies. They highlight that while fundamentals like compliance, pragmatism, and sound business principles apply across organizations, strong mitigating controls and adherence to legal and industry codes are critical.

Joseph explains the importance of engaging with various business units to understand real plans, aligning training programs with compliance needs, and avoiding pitfalls that could trigger violations of federal anti-kickback statutes. He emphasizes careful management of speakers bureau rosters, evaluating the necessity and effectiveness of healthcare professionals (HCPs) on the program, and considering fair market value while avoiding indirect remuneration risks.

The conversation also covers compensation approaches, proper documentation, and the value of third-party partners for benchmarking and compliance review. Joseph stresses that each program should be tailored to the company’s unique needs and highlights the importance of ongoing evaluation, diligence, and oversight.

Reach out to learn more.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Future-Proof Sites: SOS Insights Revealed

jeudi 27 mars 2025 • Durée 08:38

Send us Fan Mail

In this episode, Darshan Kulkarni sits down with Raymond Nomizu, founder and co-CEO of CRIO, to discuss key takeaways from the SOS conference and the evolving landscape of clinical research.

Raymond shares his journey from running a clinical research site to founding CRIO, a platform designed to modernize site operations through eSource, CTMS, and real-time data solutions. They explore major industry trends, including the rise of site networks, increasing sponsor demand for real-time data access, and the shifting role of decentralized clinical trials (DCTs).

They also discuss whether DCTs are truly revolutionizing research or simply becoming part of standard clinical operations. Raymond emphasizes that while centralization can improve efficiency in areas like finance, data management, and regulatory processes, the investigator-patient relationship must remain localized for research to be effective.

The SOS conference highlighted these ongoing shifts, and the conversation dives into how sites can stay competitive by adapting to sponsor expectations, leveraging technology, and optimizing operations.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Why Food M&A Deals Collapse—And How to Prevent It

mardi 25 mars 2025 • Durée 02:29

Send us Fan Mail

Darshan talks about a major blind spot in food M&A—hidden compliance risks that can destroy a deal overnight. While most focus on financials, market share, and synergies, they fail to account for regulatory pitfalls that can trigger investigations, recalls, or severe penalties. Imagine being deep in negotiations, only to discover unapproved ingredients, misleading health claims, or an undisclosed FDA warning letter buried in company files. Some executives make the mistake of pushing forward, thinking they’ll fix it later—but regulators like the FDA, USDA, and FTC won’t wait.

Many assume their internal legal teams can handle compliance due diligence, but food regulations are complex, spanning labeling, safety, advertising, and state consumer protection laws. The Kulkarni Law Firm specializes in identifying and resolving these risks before they become deal-breakers. We help buyers conduct regulatory due diligence, engage with federal and state regulators, assess liability risks in labeling and advertising, and structure compliance-driven transactions.

If you're involved in food M&A, don’t let compliance issues turn your investment into a liability. Reach out to the Kulkarni Law Firm to protect your deal and ensure regulatory success.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Non-Compliance Led to QOL Medical's $47M Settlement

dimanche 23 mars 2025 • Durée 02:00

Send us Fan Mail

The recent $47 million settlement involving QOL Medical and its CEO is a stark reminder of the consequences of crossing legal and ethical boundaries. Allegations of offering free Carbon 13 breath test kits as kickbacks to induce prescriptions for Sucraid, a treatment for congenital sucrose isomaltase deficiency (CSID), aren't just about non-compliance—they’re about patient safety. The breath tests could not specifically diagnose CSID but were marketed as such, leading to inappropriate prescriptions and fraudulent claims submitted to federal healthcare programs. This not only wasted resources but also put vulnerable patients at risk.

For those in the rare disease treatment space, this case highlights the need for transparency and truth in marketing. Ask yourself: Are your promotional strategies truthful? Are you offering incentives that could be misconstrued as kickbacks? In a field with limited data and high stakes, misleading marketing can erode trust, tarnish reputations, and invite legal scrutiny. Compliance is not just a checkbox—it’s a commitment to ethical practices that prioritize patient well-being. As you navigate these challenges, ensure your marketing practices are compliant while effectively educating healthcare providers about rare disease treatments. QOL Medical’s costly misstep should serve as a warning.

For guidance on staying compliant, reach out to the Kulkarni Law Firm and learn how we can help.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

FDA Regulatory Submissions: Challenges, Trends, and Future Predictions

vendredi 21 mars 2025 • Durée 02:52

Send us Fan Mail

Edye Edens from KLF offers a brief yet in-depth overview of FDA regulatory submissions for clinical research in the U.S., reflecting on both current practices and predictions for 2025. She highlights how AI tools and evolving political dynamics are shaping the regulatory landscape, emphasizing that while efficiency improvements are necessary, careful and strategic approaches are critical to maintain the FDA’s global reputation and safety standards.

Edye discusses the complexity of submissions like Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications, noting the significant preclinical work, detailed documentation, and thorough FDA review process involved. She also underscores the global weight of FDA approvals, as many international regulatory bodies rely on FDA assessments as a benchmark.

Finally, Edye poses key questions to her audience:

How familiar are you with regulatory submissions?
Are you considering outsourcing this complicated process?
Where do you see opportunities for efficiency—through AI, technology, or administrative changes?
If you’ve been a reviewer, how do you balance efficiency with safety?

Reach out for more info!

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

How to do a VR promo check - Carly Schaecter gives us her advice

mercredi 19 mars 2025 • Durée 14:42

Send us Fan Mail

Carly Schaechter discusses the potential of VR in drug promotion and the challenges of reviewing VR content for the PRC. Key points include the need for VR expertise to conceptualize interactive, engaging content. Choosing VR over AR depends on the objectives, with VR offering more controlled environments. Ensuring user control, addressing misinformation, and learning from past mistakes are crucial for successful VR implementation. Gamification and user experience evaluation are critical elements of the review process.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Diversity Matters in Clinical Trials

mardi 18 mars 2025 • Durée 05:42

Send us Fan Mail

In this insightful discussion, Shuja Naqvi, CEO of Biopharma Informatics, joins Darshan Kulkarni to explore the evolving landscape of clinical research. Shuja shares how his company has expanded across seven states, strategically choosing locations to promote diversity—not just in ethnicity, but also in socioeconomic and regional representation. He highlights the importance of gathering data from various populations to improve the effectiveness and inclusivity of clinical trials.

They delve into the growing role of research as a care option, particularly for uninsured patients who, through clinical trial participation, gain access to free medical care, medications, and life-saving screenings. While this model presents clear benefits, it also raises ethical concerns, such as the potential for undue influence when patients rely on trials for necessary healthcare. Shuja emphasizes the role of informed consent and IRB oversight in ensuring that participation remains voluntary and ethical.

The conversation also addresses compensation for trial participants. Shuja argues that current payments are insufficient, considering the risks involved in testing non-FDA-approved treatments. He stresses that researchers should ask themselves: “Would I enroll my own family in this trial?” If not, it’s a sign that ethical standards and participant compensation need to be reconsidered.

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

EMA’s LLM Guidelines Impact Life Sciences

dimanche 16 mars 2025 • Durée 02:44

Send us Fan Mail

The EMA's new guiding principles on LLMs represent a transformative step in regulatory science, addressing both the immense potential and significant risks of these technologies. These principles emphasize the need to balance innovation with ethical considerations, tackling issues like data privacy, misinformation, and bias. LLMs, such as ChatGPT, hold promise for automating workflows like medical translations, pharmacovigilance reporting, and coding support. However, the EMA stresses continuous education, ethical governance, and collaboration among stakeholders to ensure responsible use.

Key recommendations include adopting strategies like prompt engineering to optimize AI outputs and fostering collaboration through initiatives like the European Specialized Expert Community (ESEC) for AI knowledge sharing. Bite-sized, accessible training programs can also help demystify LLMs for teams. As the life sciences sector embraces these tools, organizations must align with these principles to ensure compliant and impactful AI integrations. The Kulkarni Law Firm offers expert advice for ethical AI deployment—don’t wait to make your AI strategy future-ready!

Support the show

www.kulkarnilawfirm.com

Lire plusRéduire

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à DarshanTalks Podcast. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

À propos Méthodologie Contact Me soutenir Politique de confidentialité

DarshanTalks Podcast – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Buzzsprout2

Youtube20

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Apple Podcasts

Spotify

Podcasts Similaires Basées sur le Contenu

Buzzsprout2

Youtube20

Other10